Viral Hepatitis and Thrombosis: A Narrative Review

Alessandro Squizzato; Victor E.A. Gerdes

doi:10.1055/s-0032-1305783

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2012; 38(05): 530-534
DOI: 10.1055/s-0032-1305783

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Viral Hepatitis and Thrombosis: A Narrative Review

Authors

Alessandro Squizzato

¹Research Center on Thromboembolic Disorders and Antithrombotic Therapies, Department of Clinical Medicine, University of Insubria, Varese, Italy

²Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
Victor E.A. Gerdes

²Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands

³Department of Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands

Abstract

Venous thromboembolism (VTE) is a multicausal disease. Among minor risk factors, acute infections in general are associated with a transient increased risk of VTE. However, acute hepatitis is usually not reported as a potential risk factor for VTE. Recent studies suggest a possible role of viral hepatitis in the development of VTE and, in particular, of portal vein thrombosis. In this narrative review, we will discuss the possible pathogenetic roles of cytomegalovirus, Epstein-Barr virus, and hepatitis A, B, and C viruses in VTE occurrence, and clinical evidence supporting this hypothesis. The hemostatic state in chronic liver disease and the role of coagulation in liver fibrosis will also be discussed.

Keywords

hepatitis - thrombosis - cytomegalovirus - Epstein-Barr virus - hepatitis A, B and C virus

Full Text

References

References
1 Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353 (9159) 1167-1173
2 Denninger MH, Chaït Y, Casadevall N , et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000; 31 (3) 587-591
3 Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 2006; 367 (9516) 1075-1079
4 Levi M, Keller TT, van Gorp E, ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc Res 2003; 60 (1) 26-39
5 Squizzato A, Gerdes VEA, Büller HR. Effects of human cytomegalovirus infection on the coagulation system. Thromb Haemost 2005; 93 (3) 403-410
6 Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB ; for the Italian Association of the Study of Liver Commission on Extrahepatic Manifestations of HCV infection. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis 2007; 39 (1) 2-17
7 Centers for Disease Control and Prevention (CDC). Atlanta. Available at: http://www.cdc.gov . Accessed Sept 14, 2011–09–14
8 Chanarin I, Walford DM. Thrombocytopenic purpura in cytomegalovirus mononucleosis. Lancet 1973; 2 (7823) 238-239
9 Squizzato A, Ageno W, Cattaneo A, Brumana N. A case report and literature review of portal vein thrombosis associated with cytomegalovirus infection in immunocompetent patients. Clin Infect Dis 2007; 44 (2) e13-e16
10 Delbos V, Abgueguen P, Chennebault JM, Fanello S, Pichard E. Acute cytomegalovirus infection and venous thrombosis: role of antiphospholipid antibodies. J Infect 2007; 54 (1) e47-e50
11 Justo D, Finn T, Atzmony L, Guy N, Steinvil A. Thrombosis associated with acute cytomegalovirus infection: a meta-analysis. Eur J Intern Med 2011; 22 (2) 195-199
12 Mashav N, Saar N, Chundadze T, Steinvil A, Justo D. Epstein-Barr virus-associated venous thromboembolism: a case report and review of the literature. Thromb Res 2008; 122 (4) 570-571
13 Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002; 31 (4) 256-263
14 Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol Rev 2006; 28: 101-111
15 Williams R. Global challenges in liver disease. Hepatology 2006; 44 (3) 521-526
16 Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol 2008; 103 (5) 1283-1297 , quiz 1298
17 Green AJ, Novak LJ. Thrombophlebitic prodrome in hepatitis. N Engl J Med 1971; 285 (23) 1322
18 Shoenfeld Y. Systemic antiphospholipid syndrome. Lupus 2003; 12 (7) 497-498
19 Biron C, Andreani H, Blanc P. Prevalence of antiphospholipid antibodies in patients with chronic liver disease related to alcohol or hepatitis C virus: correlation with liver injury. J Lab Clin Med 1998; 131: 243-250
20 Violi F, Ferro D, Basili S , et al. Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis. J Investig Med 1995; 43 (6) 550-554
21 Prieto J, Yuste JR, Beloqui O , et al. Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome. Hepatology 1996; 23 (2) 199-204
22 Daniels AH, Wilson CL, Harrison RA. Hepatitis C-associated leukocytoclastic vasculitis with anticardiolipin antibodies causing penile necrosis and deep venous thrombosis in the absence of cryoglobulinemia. J Hosp Med 2008; 3 (2) 170-172
23 Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112 (9) 682-698
24 Mangia A, Margaglione M, Cascavilla I , et al. Anticardiolipin antibodies in patients with liver disease. Am J Gastroenterol 1999; 94 (10) 2983-2987
25 Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365 (2) 147-156
26 Anstee QM, Dhar A, Thursz MR. The role of hypercoagulability in liver fibrogenesis. Clin Res Hepatol Gastroenterol 2011; 35 (8–9) 526-533
27 Wright M, Goldin R, Hellier S , et al. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 2003; 52 (8) 1206-1210
28 Levy GA, Liu M, Ding J , et al. Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis. Am J Pathol 2000; 156 (4) 1217-1225
29 Marsden PA, Ning Q, Fung LS , et al. The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. J Clin Invest 2003; 112 (1) 58-66
30 Nicolò M, Artioli S, La Mattina GC, Ghiglione D, Calabria G. Branch retinal artery occlusion combined with branch retinal vein occlusion in a patient with hepatitis C treated with interferon and ribavirin. Eur J Ophthalmol 2005; 15 (6) 811-814
31 Sene D, Touitou V, Bodaghi B , et al. Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C. World J Gastroenterol 2007; 13 (22) 3137-3140
32 Murata M, Tamura Y, Ohsawa M, Hirano T, Matsuo T, Murata T. Central retinal vein occlusion in hypertensive patients with chronic hepatitis C treated with interferon alpha and ribavirin. Jpn J Ophthalmol 2008; 52 (6) 511-513
33 Kim ET, Kim LH, Lee JI, Chin HS. Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin. Jpn J Ophthalmol 2009; 53 (6) 598-602
34 Balderramo DC, García O, Colmenero J, Espinosa G, Forns X, Ginès P. Antiphospholipid syndrome during pegylated interferon alpha-2a therapy for chronic hepatitis C. Dig Liver Dis 2009; 41 (7) e4-e7
35 Sugano S, Suzuki T, Watanabe M, Ohe K, Ishii K, Okajima T. Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. Am J Gastroenterol 1998; 93 (12) 2441-2444
36 Nadir A, Amin A, Chalisa N, van Thiel DH. Retinal vein thrombosis associated with chronic hepatitis C: a case series and review of the literature. J Viral Hepat 2000; 7 (6) 466-470
37 Tripodi A, Anstee QM, Sogaard KK, Primignani M, Valla DC. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost 2011; 9 (9) 1713-1723
38 Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD ; American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009; 49 (3) 1017-1044